Onconetics Pharmaceuticals, Inc.
Onconetics Pharmaceuticals is a San Francisco-based private biotech founded in 2016 developing personalized gene therapies for cancers and genetic disorders. The company has 1-10 employees and minimal public operational footprint beyond a 2017 early-stage round led by SOSV/IndieBio.
- Company typePrivate
- Founded2016
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Onconetics Pharmaceuticals, Inc. firmographics
Firmographics- Name
- Onconetics Pharmaceuticals, Inc.
- Website
- https://onconetics.com
- Company type
- Private
- Founded year
- 2016
- Headcount range
- 1–10 employees
- Short description
- Onconetics Pharmaceuticals is a San Francisco-based private biotech founded in 2016 developing personalized gene therapies for cancers and genetic disorders. The company has 1-10 employees and minimal public operational footprint beyond a 2017 early-stage round led by SOSV/IndieBio.
- Ownership category
- akta.pro rank
Onconetics Pharmaceuticals, Inc. industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Onconetics Pharmaceuticals, Inc. is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Onconetics Pharmaceuticals, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Onconetics Pharmaceuticals, Inc. product offering
Product offeringCore offering
Onconetics Pharmaceuticals is an early-stage biotechnology company developing personalized gene therapies intended for the treatment of cancers and other genetic disorders. The company's work centers on tailoring gene-based therapeutic interventions to individual patient biology, targeting oncology and inherited disease indications. No commercial products, revenue, or pricing details are publicly disclosed in the source data.
Differentiator
Problem solved
Functional benefit
Products and services
- Personalized gene therapies for cancer and genetic disorders Pre-clinical, R&D-stage development of personalized gene-based therapeutic candidates intended to treat cancers and other genetic disorders; intended for eventual use by oncology and rare disease treatment centers and their patients. No commercial product is currently available, and no product-specific page or imagery is published on the company's website.
Companies that use Onconetics Pharmaceuticals, Inc.
Customer profileIdeal customer profiles2 records
Onconetics Pharmaceuticals, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Onconetics Pharmaceuticals, Inc. competitors and assessment
Company assessmentDirect peers
- Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene-editing company developing in vivo and ex vivo therapies for oncology and genetic diseases. Directly comparable to Onconetics in modality, indication focus, and personalized gene-therapy approach.
- CRISPR Therapeutics: Pioneer in CRISPR/Cas9-based gene therapies with approved Casgevy and active programs in oncology (CAR-T) and inherited disorders. Closely aligned with Onconetics' stated dual oncology/genetic-disease focus.
- Editas Medicine: Clinical-stage gene editing company developing CRISPR-based therapies for serious diseases including oncology and inherited genetic disorders. Same therapeutic scope and modality as Onconetics.
- Beam Therapeutics: Clinical-stage base-editing company with programs in sickle cell disease, alpha-1 antitrypsin deficiency, and oncology. Highly comparable precision gene-editing modality and indication overlap.
- bluebird bio: Gene therapy company developing one-time treatments for severe genetic diseases (Skysona, Zynteglo) and oncology. Directly comparable in genetic-disease focus and AAV-based personalized approach.
- Sarepta Therapeutics: Commercial-stage gene therapy company with multiple approved AAV-based therapies for rare neuromuscular diseases and an active oncology pipeline. Comparable in rare genetic disease focus and AAV gene-therapy modality.
- uniQure: Clinical-stage gene therapy company with AAV-based programs in Huntington's disease, hemophilia, and other genetic disorders. Comparable modality and rare-disease orientation.
- Verve Therapeutics: Clinical-stage cardiovascular-focused gene-editing company using in vivo base editing. Comparable in gene-therapy modality and personalization of treatment, though focused on a distinct therapeutic area.
Emerging players
- Prime Medicine: Clinical-stage prime editing company developing therapies across oncology and genetic diseases. Comparable modality (precision gene editing) and pipeline breadth, though at a more advanced stage with significant capital.
- Caribou Biosciences: Clinical-stage allogeneic CAR-T and genome-editing company with oncology focus. Comparable in applying gene-editing tools to oncology, though emphasizing off-the-shelf cell therapy rather than fully personalized approaches.
Market position
Customer concentration
Onconetics Pharmaceuticals, Inc. social profiles
Digital presenceOnconetics Pharmaceuticals, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Onconetics Pharmaceuticals, Inc. leadership team
Management profileNumber of profiles
Onconetics Pharmaceuticals, Inc. funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Onconetics Pharmaceuticals, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Onconetics Pharmaceuticals, Inc.
What does Onconetics Pharmaceuticals, Inc. do?
Onconetics Pharmaceuticals is an early-stage biotechnology company developing personalized gene therapies intended for the treatment of cancers and other genetic disorders. The company's work centers on tailoring gene-based therapeutic interventions to individual patient biology, targeting oncology and inherited disease indications. No commercial products, revenue, or pricing details are publicly disclosed in the source data.
When was Onconetics Pharmaceuticals, Inc. founded?
Onconetics Pharmaceuticals, Inc. was founded in 2016. It employs 1 to 10 people.
Where is Onconetics Pharmaceuticals, Inc. based?
Onconetics Pharmaceuticals, Inc. is headquartered in San Francisco, United States, in the North America region.
Who are Onconetics Pharmaceuticals, Inc.'s main competitors?
Direct peers on record are Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, Beam Therapeutics, bluebird bio, Sarepta Therapeutics, uniQure and Verve Therapeutics. Emerging players are Prime Medicine and Caribou Biosciences.
Does Onconetics Pharmaceuticals, Inc. have an API?
No public API is recorded for Onconetics Pharmaceuticals, Inc..
What industry is Onconetics Pharmaceuticals, Inc. in?
Onconetics Pharmaceuticals, Inc.'s product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325414 and its SIC code is 2836.